

1 **I. TITLE PAGE**

2 **Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults**
3 **During Delta Versus Omicron Waves**

4 Margaret K. Doll, PhD, MPH^{*,a}, Alpana Waghmare, MD^{*,b,c}, Antje Heit, MD, PhD^d,
5 Brianna Levenson Shakoor, BS^e, Louise E. Kimball, PhD^c, Nina Ozbek, BS^c, Rachel L.
6 Blazevic, BS^c, Larry Mose, BS^c, Jim Boonyaratanakornkit, MD, PhD^c, Terry L. Stevens-
7 Ayers, MS^c, Kevin Cornell, MS^f, Benjamin D. Sheppard, BS^f, Emma Hampson, BS^f,
8 Faria Sharmin, MPH^a, Benjamin Goodwin, BS^e, Jennifer M. Dan, MD, PhD^{e,g}, Tom
9 Archie, MDⁱ, Terry O'Connor, MD^{f,h}, David Heckerman, MD, PhD^d, Frank Schmitz, MD,
10 PhD^d, Michael Boeckh, MD, PhD^{+,c,i}, Shane Crotty, PhD^{+,e,g}

11 *these authors contributed equally as co-first authors

12 +these authors contributed equally as co-senior authors

13 ^aDepartment of Population Health Sciences, Albany College of Pharmacy & Health
14 Sciences, Albany, NY, USA

15 ^bDivision of Infectious Diseases, Department of Pediatrics, University of Washington,
16 Seattle, WA, USA

17 ^cVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA,
18 USA

19 ^dAmazon, Inc., Seattle, WA, USA

20 ^eCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology,
21 La Jolla, California, USA

22 ^fSt. Luke's Medical Center, Ketchum, ID, USA

23 ^gDivision of Infectious Diseases and Global Public Health, Department of Medicine,
24 University of California, San Diego, La Jolla, California, USA

25 ^hDepartment of Emergency Medicine, University of Washington, Seattle, WA, USA

26 ⁱDivision of Allergy and Infectious Diseases, Department of Medicine, University of
27 Washington, Seattle, WA, USA

28

29 **Corresponding author:** Margaret K. Doll, PhD, MPH; Albany College of Pharmacy &
30 Health Sciences, 106 New Scotland Ave, HAB121A, Albany, NY 12208 • Phone:
31 518.694.7731 • Email: margaret.doll@acphs.edu

32

33 **Article Type:** Original Investigation

34 **Word Count:** 2,971 of max 3,000 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Figures/Tables:** 5 of max 5

36

37

38 **KEY POINTS** (100 of max 75-100 words or less)

39 **Question:** What are acute and post-acute outcomes among previously uninfected and
40 unvaccinated adults who contracted Omicron (BA.1/BA.2), and how do these compare
41 with Delta infections?

42 **Findings:** In this prospective cohort of 274 immunologically naïve adults, 166 (61%)
43 contracted SARS-CoV-2, with 9 (5.5%) asymptomatic infections. Compared with Delta,
44 Omicron infections experienced a 79% relative reduction in healthcare utilization, and
45 56% and 79% relative reductions in the risk and rate of post-acute symptoms (≥5-
46 weeks), respectively.

47 **Meaning:** These findings suggest among immunologically naïve adults, few infections
48 are asymptomatic, and relative to Delta, Omicron infections have lower likelihoods of
49 severe illness and post-acute symptoms.

50

52 **II. ABSTRACT** (342 of max 350 words)

53 **Importance:** The U.S. arrival of the Omicron variant led to a rapid increase in SARS-
54 CoV-2 infections. While numerous studies report characteristics of Omicron infections
55 among vaccinated individuals and/or persons with a prior history of infection,
56 comprehensive data describing infections among immunologically naïve adults is
57 lacking.

58
59 **Objective:** To examine COVID-19 acute and post-acute clinical outcomes among a
60 well-characterized cohort of unvaccinated and previously uninfected adults who
61 contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare
62 outcomes with infections that occurred during the Delta wave.

63 **Design:** A prospective cohort undergoing high-resolution symptom and virologic
64 monitoring between June 2021 and September 2022

65 **Setting:** Multisite recruitment of community-dwelling adults in 8 U.S. states

66 **Participants:** Healthy, unvaccinated adults between 30 to 64 years of age without an
67 immunological history of SARS-CoV-2 who were at high-risk of infection were recruited.
68 Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom
69 surveys and nasal swabs for SARS-CoV-2 PCR testing.

70 **Exposure(s):** Omicron (BA.1/BA.2 lineages) versus Delta SARS-CoV-2 infection,
71 defined as a positive PCR that occurred during a period when the variant represented
72 $\geq 50\%$ of circulating SARS-CoV-2 variants in the participant's geographic region.

73 **Main Outcome(s) and Measure(s):** The main outcomes examined were the
74 prevalence and severity of acute (≤ 28 days post-onset) and post-acute (≥ 5 weeks post-
75 onset) symptoms.

76 **Results:** Among 274 immunologically naïve participants, 166 (61%) contracted SARS-
77 CoV-2. Of these, 137 (83%) and 29 (17%) infections occurred during the Omicron- and
78 Delta-predominant periods, respectively. Asymptomatic infections occurred among
79 6.7% (95% CI: 3.1%, 12.3%) of Omicron cases and 0.0% (95% CI: 0.0%, 11.9%) of
80 Delta cases. Healthcare utilization among Omicron cases was 79% (95% CI: 43%, 92%,
81 $P = 0.001$) lower relative to Delta cases. Relative to Delta, Omicron infections also
82 experienced a 56% (95% CI: 26%, 74%, $P = 0.004$) and 79% (95% CI: 54%, 91%,
83 $P < 0.001$) reduction in the risk and rate of post-acute symptoms, respectively.

84 **Conclusions and Relevance:** These findings suggest that among previously
85 immunologically naïve adults, few Omicron (BA.1/BA.2) and Delta infections are
86 asymptomatic, and relative to Delta, Omicron infections were less likely to seek
87 healthcare and experience post-acute symptoms.

88 **III. MAIN TEXT** (2,971 of max 3,000 words)

89 **Introduction**

90 COVID-19 public health policies and control efforts must consider evolving clinical and
91 epidemiological features of disease.¹⁻³ Since these features can be impacted by SARS-
92 CoV-2 genomic changes, the World Health Organization recommends re-evaluation of
93 the clinical course of COVID-19 with the arrival of new SARS-CoV-2 variants.³ In
94 December 2021, the B.1.1.529 (Omicron) variant of concern became the predominant
95 SARS-CoV-2 variant circulating in the United States (U.S.), followed by a rapid rise in
96 cases. By March 2022, the U.S. seroprevalence of infection-induced SARS-CoV-2
97 antibodies was estimated to have increased by nearly 25%,⁴ with a 35% increase
98 observed among unvaccinated adults.⁵

99 Although numerous studies have found differences in Omicron variant clinical outcomes
100 compared with previous variants,⁶⁻¹¹ these findings are difficult to interpret due to
101 changes in population immunity from natural infection and/or vaccinations.¹²⁻¹⁴ To date,
102 longitudinal, community-based cohort studies examining Omicron infection
103 characteristics have predominantly studied vaccinated cohorts.^{7,15} Yet, investigating
104 clinical outcomes among immunologically naïve populations remains important to
105 understand the consequences of SARS-CoV-2 genomic variation.

106 In this study, we examined acute and post-acute (or “long”) COVID-19 clinical outcomes
107 during a period of Omicron (BA.1/BA.2 lineages) variant predominance among a
108 community-based prospective cohort of immunologically naïve adults who were at high-
109 risk of infection and undergoing high-resolution symptom and virologic surveillance. To
110 identify differences in clinical illness, we compared outcomes with study participants
111 who contracted SARS-CoV-2 during a period of Delta variant predominance.

112 **Methods**

113 ***Design, Setting, and Participants***

114 The COVID-19 Immune Protection Study (CovidIPS) is a multisite, prospective cohort
115 study designed to examine SARS-CoV-2 innate and adaptive immune responses
116 among immunologically naïve adults. To ensure an adequate sample size, participants

117 were recruited using web-based advertisements from targeted geographic locations with
118 high SARS-CoV-2 community transmission and suboptimal COVID-19 vaccination rates
119 in 8 U.S. states (AL, AZ, CA, ID, NV, OR, UT, and WA). To ensure feasibility of study
120 procedures, recruitment locations must have been within the service-region of a national
121 mobile phlebotomy company or in close-proximity to one of two research sites.

122 Volunteers were recruited between March 2021 and February 2022. At enrollment,
123 eligible volunteers were 30 to <65 years of age, without a previous history of COVID-19
124 vaccination or SARS-CoV-2 infection, and were deemed at high-risk for contracting
125 SARS-CoV-2 (supplementary methods). Volunteers were screened via an electronic
126 survey in English or Spanish. Eligible volunteers were contacted via telephone, with
127 written consent documented electronically. The Western Institutional Review Board
128 approved this study.

129 ***Data and Sample Collection***

130 Study data were collected and managed using REDCap (Research Electronic Data
131 Capture), a secure, web-based software platform designed to support data capture for
132 research studies, hosted by the Fred Hutchinson Cancer Center.^{16,17} To confirm
133 immune status upon enrollment, participants submitted a blood sample, and SARS-
134 CoV-2 receptor binding domain (RBD) IgG endpoint titers were quantified. Participants
135 who had either a positive RBD IgG or a borderline RBD IgG and positive nucleocapsid
136 IgG were excluded from the study. Following enrollment, participants completed a
137 baseline questionnaire, and began weekly “routine” procedures for 24 weeks consisting
138 of both: (i) an electronic survey to report COVID-19 symptoms, and (ii) a self-collected
139 nasal swab submitted for SARS-CoV-2 reverse transcription polymerase chain
140 reactions (RT-PCR) testing (supplementary methods). If a participant reported COVID-
141 19 symptoms or had a RT-PCR-positive swab, the participant was placed on
142 “enhanced” procedures consisting of: (i) daily, electronic symptom surveys and (ii) self-
143 collected nasal swabs submitted every other day, for up to 14-days. Participants who
144 were SARS-CoV-2 positive and reported symptoms (or did not complete their daily
145 symptom survey) on day 14 of enhanced procedures were sent symptom surveys for an
146 additional 14 days (*i.e.*, through day 28 post-initiation of enhanced procedures).

147 After 24 weeks, participants completed an end of study blood draw and questionnaire.
148 Participants were also offered an opportunity to re-consent for an additional 24-weeks of
149 follow-up, consisting of the same study procedures as the previous 24-weeks.

150 ***Exposure ascertainment***

151 SARS-CoV-2 infection was defined as ≥ 1 RT-PCR-positive result with an infection index
152 date during the time periods that Delta or Omicron (BA.1/BA.2) variants represented the
153 predominant ($\geq 50\%$) SARS-CoV-2 variant circulating in the participant's geographic
154 region. Weighted, regional NowCast model estimates from the U.S. Centers for Disease
155 Control and Prevention's national genomic surveillance system were used to ascertain
156 dates to categorize Omicron (BA.1/BA.2) versus Delta infections (supplemental
157 methods).¹⁸

158 The infection index date was defined as the first of either the participant's symptom
159 onset or first SARS-CoV-2 RT-PCR-positive swab collection date. Symptom onset dates
160 were determined by participant self-report; where missing, the first date a symptom was
161 reported on surveys was used.

162 ***Outcome ascertainment***

163 Acute COVID-19 symptoms were defined as symptoms within 28 days of the
164 participant's symptom onset date, which represents a time period frequently used to
165 demarcate the transition to post-COVID conditions.¹⁹⁻²¹ To minimize misclassification
166 due to nonspecific conditions, a window of ± 14 days within the collection date of the first
167 RT-PCR positive result was used to examine COVID-19 symptoms; to be considered
168 asymptomatic, participants must have both: (i) denied symptoms in all surveys
169 submitted during this time period, and (ii) submitted at least one survey indicating they
170 did not have symptoms 7 or more days after RT-PCR testing to ensure sufficient follow
171 up.² Post-acute symptoms were defined as any symptom the participant reported as
172 "related to their previous COVID-19 illness" 5 weeks or more after symptom onset (or
173 first PCR positive for asymptomatic participants); this time period was selected because
174 it was consistent with study procedures (*i.e.*, a return to weekly procedures at up to 28
175 days following enhanced procedures), and common definitions of post-COVID

176 conditions as symptoms experienced at least 4 weeks after infection.¹⁹⁻²¹ In sensitivity
177 analyses, we explored alternate post-acute definitions modifying this time period, the
178 number of surveys required with reports of post-acute symptoms, and/or post-acute
179 symptoms considered. Participants recorded post-acute symptoms in routine weekly
180 surveys until the first of either the participant's study end date or the analyses end date
181 (September 9, 2022).

182 **Statistical Analyses**

183 Risks and 95% confidence intervals (CI) of acute asymptomatic infections and post-
184 acute symptoms were estimated overall and by variant among participants
185 immunologically naïve at the time of infection; relative risks (*RR*) and 95% CI were
186 estimated comparing Omicron with Delta (referent) infections. Where *RR* could not be
187 estimated (due to zero outcomes among the referent group), absolute risk differences
188 and 95% CI were estimated. To account for differences in post-acute symptom follow up
189 time by variant, rate ratios with 95% CI were estimated using a generalized estimating
190 equation (GEE) approach with a Poisson distribution and offset term to account for
191 completed surveys. In these analyses, a robust “sandwich” covariance estimator with
192 small sample size correction was used to estimate 95% CI using an exchangeable
193 correlation structure.^{22,23} These models were extended to include multivariable
194 adjustment for participant age (continuous) and gender (binary).

195 Descriptive analyses were performed to analyze the prevalence, mean number, and
196 mean severity of acute or post-acute symptoms in relation to participant symptom onset.
197 Exploratory multivariable analyses were also conducted to examine the relationship
198 between acute illness and post-acute symptoms (supplemental methods).

199 Baseline and end of study self-rated overall health, memory and concentration, and
200 ability to walk or climb stairs were compared by SARS-CoV-2 variant. For each variable,
201 a change score analysis was performed, comparing the difference in the participant's
202 end of study response from baseline after adjustment for their baseline score; an alpha
203 level of <0.05 was used to denote statistical significance. In primary analyses, Omicron
204 and Delta infections were directly compared; in secondary analyses, each variant was

205 compared with participants who remained naïve at the end of study survey. For
206 inclusion in either analysis, SARS-CoV-2-positive participants must have had ≥ 5 weeks
207 between their end of study survey and symptom onset (or first PCR-positive date for
208 asymptomatic participants).

209 All analyses were conducted using RStudio with R version 4.2.0 (The R Foundation for
210 Statistical Computing, Vienna, Austria).

211 **Results**

212 During the study period, 274 immunologically naïve participants were enrolled in the
213 CovidIPS cohort. Among these participants, 166 (61%) became SARS-CoV-2 RT-PCR-
214 positive without a prior history of vaccination or disease; 137 (83%) and 29 (17%)
215 infections occurred during the Omicron- and Delta-predominant periods, respectively.
216 Acute symptom data was available for 164 (99%) infections, post-acute symptom data
217 was available for 150 (90%) infections, and end of study survey data ≥ 5 -weeks post-
218 infection were available for 133 (80%) participants.

219 Demographics of the CovidIPS cohort are compared by infection status in Supplemental
220 Results Table 1, and a study flow diagram is provided in Supplemental Figure 1.

221 ***Acute symptoms and healthcare utilization***

222 Among the 164 first-time infections with acute survey data, 9 (5.5%, 95% CI: 2.5%,
223 10.2%) did not report symptoms and were classified as asymptomatic. Stratified by
224 variant, 0.0% (95% CI: 0.0%, 11.9%) of Delta and 6.7% (95% CI: 3.1%, 12.3%) of
225 Omicron infections were asymptomatic, representing a 6.7% (95% CI: 2.5%, 10.9%,
226 $P = 0.002$) absolute risk reduction in symptomatic illness among Omicron infections.

227 Acute symptom prevalence and severity among the 155 symptomatic infections are
228 examined by days since onset in Figures 1 and 2, while the mean daily number of acute
229 symptoms are examined in Supplemental Figure 2. In general, the prevalence of
230 COVID-19 symptoms was similar by variant; however, participants with Delta infections
231 appeared more likely to report a loss of taste or smell and rate these symptoms with a
232 higher mean severity.

233 Overall, 8.5% (95% CI: 4.7%, 13.9%) of participants sought healthcare for acute
234 symptoms, with no participants requiring emergency care or hospitalization. The *RR* of
235 any healthcare utilization was 79% (95% CI: 43%, 92%) lower among Omicron relative
236 to Delta infections ($RR = 0.21$, 95% CI: 0.08, 0.57, $P=0.001$). Overall, 5.5% (95% CI:
237 2.5%, 10.2%) of participants received a prescribed medication (supplemental results),
238 with an 83% (95% CI: 40%, 95%, $P= 0.002$) *RR* reduction among Omicron relative to
239 Delta infections.

240 ***Post-acute symptoms***

241 Among 150 participants with post-acute data, 123 and 27 participants were infected
242 during the Omicron- and Delta-predominant periods, respectively. Overall, 39 (26.0%,
243 95% CI: 19.2%, 33.8%) participants reported at least one symptom during the post-
244 acute period. Stratified by variant, 21.1% (95% CI: 14.3%, 29.4%) of Omicron cases
245 and 48.1% (95% CI: 28.7%, 68.1%) of Delta cases reported post-acute symptoms,
246 representing a 56% (95% CI: 26%, 74%) *RR* reduction in post-acute symptoms ($RR =$
247 0.44 , 95% CI: 0.26, 0.74; $P=0.004$) among Omicron participants. When analyzed as a
248 rate, Omicron and Delta infections experienced post-acute symptoms 4.9 (95% CI: 3.9,
249 5.9) per 100 person-weeks and 29.2 (95% CI: 25.4, 33.1) per 100 person-weeks,
250 respectively, representing a rate ratio of 0.21 (95% CI: 0.09, 0.46, $P<0.001$) among
251 Omicron versus Delta infections. Similar rate ratio reductions were found after
252 adjustment for participant age and gender (data not shown). Results from sensitivity
253 analyses demonstrated similar *RR* reductions for most (5/6) modified post-acute
254 definitions (Table 1). In general, the magnitude of *RR* reductions among Omicron
255 participants were more pronounced under more stringent post-acute definitions;
256 however, *RR* estimates were imprecise. A definition examining only cognitive post-acute
257 symptoms found no difference between variants.

258 We examined mean severity of post-acute symptoms by variant and individual post-
259 acute symptom trajectories in Supplemental Figures 3 and 4, respectively. To ensure
260 comparability, analyses were restricted to 142 (94.7%) unvaccinated participants who
261 did not experience SARS-CoV-2 re-infection; 33 (22 Omicron, 11 Delta) reported post-
262 acute symptoms. While these analyses represent small numbers of participants, they

263 may suggest differences in post-acute symptom severity by strain, with Delta infections
264 reporting higher mean severity and frequencies of post-acute symptoms.

265 Given the small number of participants with post-acute symptoms, we grouped Delta
266 and Omicron infections together to examine relationships between acute illness and
267 post-acute symptoms. Figure 3 and Supplemental Figures 5 and 6 examine the total
268 number of distinct symptoms, prevalence of acute symptoms, and symptom severity
269 among these participants by post-acute status, while results from exploratory
270 multivariable analyses examining the relationship between acute and post-acute
271 outcomes are reported in Supplemental Results Table 2. In general, these analyses
272 suggest that increasing acute symptom severity, particularly during the first two weeks
273 of acute illness, is associated with higher relative odds/rates of post-acute symptoms,
274 and that prevalence of many acute symptoms was greater among participants who
275 experienced post-acute symptoms.

276 ***Changes in baseline and end of study self-rated scores***

277 Among the 133 (23 Delta, 110 Omicron) participants with end of study data ≥ 5 -weeks
278 following symptom onset, no changes were detected by variant in self-rated measures
279 for overall health, memory or concentration, or physical abilities between enrollment and
280 end of study surveys (Figure 4). These results were similar for primary analyses
281 comparing variants directly, and secondary analyses comparing each variant to
282 participants who remained naïve at their end of study survey (n=90, Figure 4).

283 **Discussion**

284 In this study, we describe COVID-19 acute and post-acute outcomes in a well-
285 characterized, community-based, prospective cohort of unvaccinated and previously
286 uninfected healthy adults at high risk of infection. Our data demonstrate that SARS-
287 CoV-2 infections during the Omicron (BA.1/BA.2) period were associated with
288 significantly lower absolute risks of acute symptomatic infections, and significant relative
289 reductions in healthcare utilization for acute illness and post-acute symptoms at ≥ 5
290 weeks in comparison with Delta variant infections. While several studies have also
291 found lower acute severity of Omicron compared with Delta infections, these studies

292 have included predominantly vaccinated populations.^{7,11} To our knowledge, this is the
293 first study to characterize both acute and post-acute symptoms in a cohort of
294 immunologically naïve individuals in the era of widespread vaccination and increased
295 SARS-CoV-2 seroprevalence using prospective surveillance.

296 Defining the spectrum of COVID-19 illness for SARS-CoV-2 variants remains important
297 to elucidate the clinical consequences of SARS-CoV-2 genomic variation.¹⁻³ For these
298 purposes, exploring outcomes among unvaccinated and previously uninfected persons
299 may be of particular significance for understanding the natural course of infection in the
300 absence of pre-existing host immunity, facilitating comparisons between variants, and
301 identifying the impact of COVID-19 among non-naïve populations, should immunity
302 wane to levels that do not influence clinical illness.

303 Importantly, as COVID-19 hospitalization and mortality rates have fallen, other
304 endpoints, such as symptom prevalence and severity, have become critical to
305 characterize the impact of different variants. In the present study, we evaluated
306 epidemiological characteristics of mild COVID-19 illness using a prospective cohort
307 design with frequent and high-resolution symptom and virologic surveillance. With these
308 rigorous methods, we were able to provide key insights regarding the prevalence of
309 asymptomatic infections, which are difficult to ascertain using cross-sectional designs
310 that cannot distinguish between pre-symptomatic or asymptomatic infection,² or cohorts
311 recruited at a healthcare setting, which may be increasingly unrepresentative of mild
312 disease in an era of pervasive at-home SARS-CoV-2 diagnostics.²⁴ Overall, we found
313 that the prevalence of asymptomatic infections was only 6% among all SARS-CoV-2
314 infections, with a significantly higher absolute prevalence among Omicron (7%) versus
315 Delta (0%) infections. Our estimates of asymptomatic Omicron infections were lower
316 when compared with a recent systematic review and meta-analysis, which also found a
317 significantly higher proportion of asymptomatic infections among Omicron (25%) versus
318 Delta (8%) infections.²⁵ This apparent difference may reflect characteristics of our study
319 cohort, who represent previously immunologically naïve adults, 30 to 64 years of age,
320 factors also associated with a lower prevalence of asymptomatic disease.²⁵

321 Our prospective design also enabled us to estimate risks of post-acute or “long” COVID-
322 19 symptoms among a fully enumerated cohort of SARS-CoV-2 infections, which may
323 be more accurate than designs that recruit participants at healthcare settings or
324 following the development of post-acute symptoms.¹ We found that approximately one-
325 quarter (26%) of participants experienced at least one post-acute symptom ≥ 5 -weeks
326 following their infection. Our study is also among few to date that compared the risks of
327 post-acute COVID-19 symptoms by variant, and the only study (to our knowledge) that
328 compared post-acute risks among unvaccinated individuals. We found that risks of post-
329 acute symptoms at ≥ 5 weeks differed significantly by variant, with approximately one-
330 fifth (21%) of Omicron infections versus nearly one-half (48%) of Delta infections
331 experiencing post-acute symptoms, representing a relative risk reduction of more than
332 50% or a rate ratio reduction of 79% among Omicron infections. These findings
333 remained robust under more stringent definitions of post-acute symptoms examining
334 symptoms at ≥ 8 - and ≥ 12 -weeks. Our results were also similar to results from a study of
335 vaccinated individuals, which found 59% to 77% reductions in the odds of post-acute
336 symptoms among Omicron relative to Delta infections.²⁶

337 This study has several strengths. Our recruitment methods and prospective design
338 enabled us to ascertain participant baseline immune status with greater certainty than
339 studies using administrative data. Our study procedures also featured frequent
340 symptom and virologic surveillance with few missing data and high retention of study
341 participants, allowing us to characterize outcomes with greater accuracy than cohorts
342 ascertained following infection. Further, the distribution of SARS-CoV-2 infections
343 across Delta and Omicron time periods permitted us to compare and detect significant
344 differences in variant outcomes using the same study procedures. Finally, during an era
345 of widespread infections and vaccinations, our study population of immunologically
346 naïve adults also represents a unique cohort, who at the time of the study, comprised a
347 significant proportion of the U.S. population, yet remain underrepresented in scientific
348 research.

349 Our study also has several limitations. We did not sequence viral samples and used
350 U.S. regional prevalence data to classify variants for our SARS-CoV-2 infections. While

351 this approach is similar to methods in previous studies,^{7,26} it is possible that variants
352 were misclassified. Due to the prospective nature of our study and our unique study
353 cohort, our sample size was also smaller in comparison with studies using
354 administrative data.

355 In conclusion, we demonstrate that among a community-based cohort of
356 immunologically naïve adults, SARS-CoV-2 infections during Omicron (BA.1/BA.2) and
357 Delta predominant periods were associated with few asymptomatic cases of COVID-19
358 illness, and that Omicron infections were less likely to seek healthcare for acute
359 symptoms and more than half as likely to experience post-acute symptoms relative to
360 Delta infections. Continued study and comparisons of clinical illness from SARS-CoV-2
361 variants are critical to understand the implications of SARS-CoV-2 genomic variation
362 and must be considered with regard to host immune status.

363 **Acknowledgments**

364 **Funding**

365 The current work was funded by the NIH NIAID under awards AI142742 (Cooperative
366 Centers for Human Immunology, CCHI) (S.C.), and a supplement to NIH AI142742.

367 This work was additionally supported in part by LJI Institutional Funds, and the NIAID
368 under K08 award AI135078 (J.M.D.).

369 **Conflicts of Interest**

370 MKD has received research support from St. Luke's Wood River Foundation. AW
371 served as an advisory board member for Kyorin Pharmaceutical, and received research
372 support from GSK, Vir Biotechnology, Pfizer, Allovir, Ansun Biopharma and Amazon (all
373 for work outside this study). AH, DH, and FS are employed by and hold equity in
374 Amazon. JB received research support from GSK and IgM Biosciences (all for work
375 outside this study). MB served as a consultant for Vir Biotechnology, Merck, and
376 Moderna, and received research support from GSK, Vir Biotechnology, Merck,
377 Ridgeback, Amazon, and Regeneron. SC has consulted for GSK, JP Morgan, Citi,
378 Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California
379 State Universities, United Airlines, Adagio, and Roche.

380 IV. REFERENCES

- 381 1. Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post-acute COVID-19 syndrome
382 symptoms at different follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect.*
383 May 2022;28(5):657-666. doi:10.1016/j.cmi.2022.01.014
- 384 2. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic
385 review and meta-analysis. *Proc Natl Acad Sci U S A.* Aug 24 2021;118(34)doi:10.1073/pnas.2109229118
- 386 3. World Health Organization. World Health Organization, WHO R&D Blueprint COVID-19 new
387 variants: Knowledge gaps and research. Accessed August 11, 2022.
388 [https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-](https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-report_20.03.2022.pdf?sfvrsn=5ac5785_3&download=true)
389 [report_20.03.2022.pdf?sfvrsn=5ac5785_3&download=true](https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-report_20.03.2022.pdf?sfvrsn=5ac5785_3&download=true)
- 390 4. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies
391 - United States, September 2021-February 2022. *MMWR Morb Mortal Wkly Rep.* Apr 29
392 2022;71(17):606-608. doi:10.15585/mmwr.mm7117e3
- 393 5. Alejo JL, Chiang TPY, Mitchell J, et al. Incidence of SARS-CoV-2 infection among unvaccinated US
394 adults during the Omicron wave. *J Intern Med.* Aug 10 2022;doi:10.1111/joim.13555
- 395 6. Bouton TC, Atarere J, Turcinovic J, et al. Viral dynamics of Omicron and Delta SARS-CoV-2
396 variants with implications for timing of release from isolation: a longitudinal cohort study. *medRxiv.* Apr
397 5 2022;doi:10.1101/2022.04.04.22273429
- 398 7. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital
399 admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant
400 dominance: a prospective observational study from the ZOE COVID Study. *Lancet.* Apr 7
401 2022;doi:10.1016/S0140-6736(22)00327-0
- 402 8. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough,
403 Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019
404 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
405 *Am J Pathol.* Apr 2022;192(4):642-652. doi:10.1016/j.ajpath.2022.01.007
- 406 9. Fall A, Eldesouki RE, Sachithanandham J, et al. A Quick Displacement of the SARS-CoV-2 variant
407 Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and
408 Comparable Upper Respiratory Viral Loads. *medRxiv.* Jan 28 2022;doi:10.1101/2022.01.26.22269927
- 409 10. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA
410 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
411 prospective observational study. *BMJ.* Mar 9 2022;376:e069761. doi:10.1136/bmj-2021-069761
- 412 11. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
413 death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
414 cohort study. *Lancet.* Apr 2 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7
- 415 12. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2
416 Omicron Variant. *N Engl J Med.* Feb 17 2022;386(7):e14. doi:10.1056/NEJMp2119682
- 417 13. Strasser Z, Hadavand A, Murphy S, Estiri H. SARS-CoV-2 Omicron Variant is as Deadly as Previous
418 Waves After Adjusting for Vaccinations, Demographics, and Comorbidities. *ResearchSquare Preprint.*
419 2022;doi:<https://doi.org/10.21203/rs.3.rs-1601788/v1>
- 420 14. Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? *Nat Rev*
421 *Immunol.* Feb 2022;22(2):69-71. doi:10.1038/s41577-022-00678-4
- 422 15. Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity of the SARS-
423 CoV-2 Omicron variant. *medRxiv.* 2022:2022.01.13.22269257. doi:10.1101/2022.01.13.22269257
- 424 16. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
425 community of software platform partners. *Journal of Biomedical Informatics.* 2019/07/01/
426 2019;95:103208. doi:<https://doi.org/10.1016/j.jbi.2019.103208>
- 427 17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
428 (REDCap)—A metadata-driven methodology and workflow process for providing translational research

- 429 informatics support. *Journal of Biomedical Informatics*. 2009/04/01/ 2009;42(2):377-381.
430 doi:<https://doi.org/10.1016/j.jbi.2008.08.010>
- 431 18. Centers for Disease Control and Prevention. COVID Data Tracker: Nowcast. Atlanta, GA: US
432 Department of Health and Human Services. Accessed September 9,, 2022. [https://covid.cdc.gov/covid-](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)
433 [data-tracker/#variant-proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)
- 434 19. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. Accessed
435 September 12,, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>
- 436 20. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post
437 COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis*. Apr 16
438 2022;doi:10.1093/infdis/jiac136
- 439 21. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7
440 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
- 441 22. Fay MP, Graubard BI. Small-sample adjustments for Wald-type tests using sandwich estimators.
442 *Biometrics*. Dec 2001;57(4):1198-206. doi:10.1111/j.0006-341x.2001.01198.x
- 443 23. Kim J, Troxel AB, Halpern SD, et al. Analysis of multicenter clinical trials with very low event
444 rates. *Trials*. Nov 9 2020;21(1):917. doi:10.1186/s13063-020-04801-5
- 445 24. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23,
446 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep*. Apr 1 2022;71(13):489-494.
447 doi:10.15585/mmwr.mm7113e1
- 448 25. Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic infection and
449 nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis. *J Med*
450 *Virology*. Aug 12 2022;doi:10.1002/jmv.28066
- 451 26. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta
452 versus omicron variants of SARS-CoV-2. *The Lancet*. 2022;399(10343):2263-2264. doi:10.1016/S0140-
453 6736(22)00941-2
454
455

456 **Table 1.** Modified definitions, risks, and risk ratios (*RR*) of post-acute symptoms comparing Omicron versus Delta (referent) variant infections.


Definition	# Weeks	# Surveys with symptoms	Symptoms	Risk - Omicron (BA.1/BA.2) % (95% CI)	Risk – Delta (B.1.617.2) % (95% CI)	Risk Ratio (95% CI)	P-value
1*	≥5	≥1	Any	21% (14%, 29%)	48% (29%, 68%)	0.4 (0.3, 0.7)	0.004
2	≥5	≥1	Cognitive ⁺ only	12% (7%, 19%)	15% (4%, 34%)	0.8 (0.3, 2.3)	0.7
3	≥5	≥2	Any	13% (8%, 20%)	41% (22%, 61%)	0.3 (0.2, 0.6)	<0.001
4	≥8	≥1	Any	20% (13%, 28%)	44% (25%, 65%)	0.4 (0.3, 0.8)	0.008
5	≥8	≥2	Any	8% (4%, 14%)	37% (19%, 58%)	0.2 (0.1, 0.5)	<0.001
6	≥12	≥1	Any	10% (5%, 17%)	42% (23%, 63%)	0.2 (0.1, 0.5)	<0.001
7	≥12	≥2	Any	4% (1%, 9%)	35% (17%, 56%)	0.1 (0.0, 0.3)	<0.001

457 ^{*}*Definition 1*: used for primary analyses; ⁺*Cognitive symptoms* defined as reports of any of the following symptoms: changes in mood, confusion, extreme fatigue, inability to concentrate, insomnia,
 458 or memory lapses

459

460
461


Figure 1. Prevalence of acute COVID-19 symptoms by variant. Data represents the percentage of symptoms reported among participants who submitted a survey each day; only symptomatic persons were included (n=155). *Abbreviations:* EET: eyes, ears, and throat; GI: gastrointestinal.



462

463
464


Figure 2. Mean severity of acute COVID-19 symptoms by variant. Data represents the mean severity rating for each symptom among participants who submitted a survey each day; only symptomatic persons were included (n=155). *Abbreviations:* EET: eyes, ears, and throat; GI: gastrointestinal.



465


466
467

Figure 3. Histogram of distinct acute symptoms reported by week and post-acute symptom status; only unvaccinated and persons with one episode of SARS-CoV-2 were included (n=142).



468

469 **Figure 4.** Comparison of participant enrollment and end of study self-rated scores for
 470 health (highest health = 5), concentration & memory (highest abilities = 4), and ability to
 471 walk & climb stairs (highest abilities = 4). Dots represent the proportion of participants
 472 by variant/SARS-CoV-2 status whose responses align with a given survey pattern.
 473 Areas shaded in red represent a decline in health scores at the end of study survey,
 474 while shaded blue areas represent a positive health gain at the end of study.



475